Enhanced Half-Life Recombinant Factor VIII Concentrates for Hemophilia A: Final Results from Extension Studies

Matteo Nicola Dario Di Minno; Alessandro Di Minno; Ilenia Calcaterra; Ernesto Cimino; Francesco Dell'Aquila; Massimo Franchini

doi:10.1055/s-0041-1740148

Seminars in Thrombosis and Hemostasis, Table of Contents

Semin Thromb Hemost 2022; 48(02): 253-255
DOI: 10.1055/s-0041-1740148

Letter to the Editor

Enhanced Half-Life Recombinant Factor VIII Concentrates for Hemophilia A: Final Results from Extension Studies

Matteo Nicola Dario Di Minno

¹Department of Translational Medical Sciences, Federico II University, Naples, Italy

,

Alessandro Di Minno

²Dipartimento di Farmacia, Università degli Studi di Napoli “Federico II,” Napoli, Italy

,

Ilenia Calcaterra

³Department of Clinical Medicine and Surgery, Federico II University, Naples, Italy

,

Ernesto Cimino

³Department of Clinical Medicine and Surgery, Federico II University, Naples, Italy

,

Francesco Dell'Aquila

³Department of Clinical Medicine and Surgery, Federico II University, Naples, Italy

,

Massimo Franchini

⁴Department of Haematology and Transfusion Medicine, “Carlo Poma” Hospital, Mantua, Italy

› Author Affiliations

Abstract

Full Text

References

References
1 Horneff R, Bystrická L, Santagostino E, Lethagen S, Casiano S. Comment on “Enhanced half-life recombinant factor VIII concentrates for hemophilia A: insights from pivotal and extension studies”. Semin Thromb Hemost 2021; 48 (01) 251-252
2 Di Minno MND, Di Minno A, Calcaterra I, Cimino E, Dell'Aquila F, Franchini M. Enhanced half-life recombinant factor VIII concentrates for hemophilia A: insights from pivotal and extension studies. Semin Thromb Hemost 2021; 47 (01) 32-42
3 Mannucci PM, Cortesi PA, Di Minno MND, Sanò M, Mantovani LG, Di Minno G. Comparative analysis of the pivotal studies of extended half-life recombinant FVIII products for treatment of haemophilia A. Haemophilia 2021; 27 (04) e422-e433
4 Nolan B, Mahlangu J, Pabinger I. et al. Recombinant factor VIII Fc fusion protein for the treatment of severe haemophilia A: final results from the ASPIRE extension study. Haemophilia 2020; 26 (03) 494-502
5 Reding MT, Pabinger I, Holme PA. et al. Confirmed long-term safety and efficacy of prophylactic treatment with BAY 94-9027 in severe haemophilia A: final results of the PROTECT VIII extension study. Haemophilia 2021; 27 (03) e347-e356
6 Chowdary P, Mullins ES, Konkle BA. et al. Long-term safety and efficacy results from the phase 3b, open-label, multicentre Continuation study of rurioctocog alfa pegol for prophylaxis in previously treated patients with severe haemophilia A. Haemophilia 2020; 26 (04) e168-e178
7 Giangrande P, Abdul Karim F, Nemes L. et al. Long-term safety and efficacy of N8-GP in previously treated adults and adolescents with hemophilia A: final results from pathfinder2. J Thromb Haemost 2020; 18 (01, Suppl 1): 5-14
8 Manco-Johnson MJ, Warren BB, Buckner TW, Funk SM, Wang M. Outcome measures in haemophilia: beyond ABR (annualized bleeding rate). Haemophilia 2021; 27 (Suppl. 03) 87-95